On August 28–31, 2026, three Malaysian research houses published their reads on Karex Bhd's FY26 results, and the consensus is unusually specific about where the world's largest condom manufacturer goes next: patented nitrile condoms, price increases, and nine new markets. CIMB Research forecasts Karex's core net profit recovering to RM19.7 million in FY27 — up 452% year-on-year, though from an unmistakably low base — with RHB Research calling FY27 "a structural turning point" and Kenanga Research framing it more cautiously as "a margin-led earnings recovery year rather than a broad-based volume recovery."

Why It Matters

Karex manufactures a substantial share of the world's condoms, much of it under other companies' labels, which makes its cost structure a leading indicator for barrier contraception pricing globally — including for the Durex and Trojan-branded products sitting in mainstream retail. A 20–30% cumulative ASP increase against early-FY25 does not stay inside the factory; it eventually shows up in wholesale sheets and, more slowly, on shelves and in public-health procurement budgets. The material shift deserves attention on its own terms. Condom innovation has been mostly incremental for two decades — thinner latex, new lubricants, custom sizing at the margins — and nitrile is the rare change at the substrate level, addressing latex allergy while claiming better heat transfer and thinness. That Karex has patented its version and is expanding market-by-market through regulatory approvals is a reminder that barrier contraception is a medical device business with all the clearance overhead that implies, not a fast-moving consumer goods category. There is a public-health footnote in the numbers too. The 20.7% contraction in Karex's medical segment and the "lower tender volumes" language point at softening institutional demand — the government and NGO bulk purchases that keep condoms cheap and available in low- and middle-income markets. Against a backdrop of rising STI rates in several regions and squeezed global health budgets, a manufacturer pivoting from low-margin tender volume toward higher-ASP branded synthetics is a rational business move with an uncomfortable distributional edge. The company that makes the most condoms in the world is, for entirely defensible reasons, becoming somewhat less interested in making the cheapest ones.

FY26 itself was rough, and the details are worth reading for anyone modeling the category. Karex's sexual wellness segment contracted 6.6% year-on-year and its medical segment fell 20.7%. Despite stronger synthetic condom sales, the top line was weighed down by ringgit appreciation against the dollar and lower tender volumes — the institutional and NGO bulk contracts that have historically anchored the business. Gross margin slipped 0.2 percentage points on higher input costs, while operating expenses and US import tariffs compressed EBITDA margin by 1.5 points to 8.7%. The company posted a core net loss of RM1.2 million in 4Q26 after adjusting for RM5 million in one-off gains, most of it a RM5.6 million refund of US import tariffs paid during the first nine months of FY26 after the US rate dropped from 19% to 10% effective March 2.

The nitrile thesis is the interesting part. Latex is the incumbent material and the source of the category's most persistent friction point — allergy, plus the thickness/sensitivity tradeoff. Karex's patented nitrile condoms are a synthetic alternative it can charge more for and defend on IP, and the rollout is regulatory-gated: the company reached 21 markets by end-FY26 and targets nine more in FY27, each requiring its own approvals. CIMB expects the ramp to stay gradual through the first half of FY27 while an OEM customer destocks the existing variant ahead of a new version, with restocking in 2H27, complemented by stronger latex demand against a tighter global supply backdrop.

Then there's pricing. RHB notes that Karex's 5–15% price increases were not fully reflected in 4Q26 and that cumulative uplift should reach 20–30% versus early-FY25 average selling prices. Combined with normalizing raw material costs, RHB expects meaningful margin expansion from FY27. CIMB maintained a "buy" with a 70 sen target price; RHB kept a "buy" at 56 sen while trimming FY27–FY28 earnings by 1% each. The spread between those two targets is itself a fair summary of the uncertainty: everyone agrees the direction is up, nobody agrees on how far.

Sources

Update — 2026-08-31

{Initial entry — story first created.}